PharmacoEconomics : Impact Factor & More
eISSN: 1179-2027pISSN: 1170-7690
Share this on:
Aims and Scope of PharmacoEconomics
PharmacoEconomics is a peer-reviewed medical journal published by Adis International (Springer Nature) that covers the fields of health economics, pharmacoeconomics, and quality-of-life assessment.
Key Metrics
CiteScore 
7.5
Eigenfactor
0.005 - 0.01
H-Index
112
Impact Factor
< 5
SJR
Q1Pharmacology
SNIP
1.85
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on PharmacoEconomics
PharmacoEconomics Journal Specifications
| Overview | |
| Publisher | ADIS INT LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1992 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in PharmacoEconomics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in PharmacoEconomics
Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing Arthroplasty.
- 1 Jul 2026
- PharmacoEconomics
Lifetime Effects of Adherence to Cardiovascular and Diabetes Medications in Spain: A Modelling Study in a Population Cohort of 152,117 Patients.
- 1 Jul 2026
- PharmacoEconomics
What is the Value of Developing an HTA Process?
- 1 Jul 2026
- PharmacoEconomics
The Economic Burden of Duchenne Muscular Dystrophy: A Systematic Review.
- 1 Jul 2026
- PharmacoEconomics
Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.
- 1 Jul 2026
- PharmacoEconomics
Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.
- 23 Jun 2026
- PharmacoEconomics
Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing Arthroplasty.
- 1 Jul 2026
- PharmacoEconomics
Lifetime Effects of Adherence to Cardiovascular and Diabetes Medications in Spain: A Modelling Study in a Population Cohort of 152,117 Patients.
- 1 Jul 2026
- PharmacoEconomics
What is the Value of Developing an HTA Process?
- 1 Jul 2026
- PharmacoEconomics
The Economic Burden of Duchenne Muscular Dystrophy: A Systematic Review.
- 1 Jul 2026
- PharmacoEconomics
Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.
- 1 Jul 2026
- PharmacoEconomics
Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.
- 23 Jun 2026
- PharmacoEconomics
FAQs on PharmacoEconomics
How long has PharmacoEconomics been actively publishing? 
What is the publishing frequency of PharmacoEconomics?
How many articles did PharmacoEconomics publish last year?
What is the eISSN & pISSN for PharmacoEconomics?
What is Citescore for PharmacoEconomics?
What is the H Index for PharmacoEconomics ?
What is SNIP score for PharmacoEconomics?
What is the SJR for PharmacoEconomics?
Who is the publisher of PharmacoEconomics?
